{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:48:19Z","timestamp":1768016899641,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R21AA030335"],"award-info":[{"award-number":["R21AA030335"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20KK0185"],"award-info":[{"award-number":["20KK0185"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15971"],"award-info":[{"award-number":["22K15971"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA270795"],"award-info":[{"award-number":["R01CA270795"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.canlet.2023.216493","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:00:27Z","timestamp":1700074827000},"page":"216493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase"],"prefix":"10.1016","volume":"580","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-6101","authenticated-orcid":false,"given":"Katsuya","family":"Nagaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-0404","authenticated-orcid":false,"given":"Joud","family":"Mulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-4150","authenticated-orcid":false,"given":"Hongze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-6365","authenticated-orcid":false,"given":"Muhammad Azhar","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2870-5793","authenticated-orcid":false,"given":"Shaolei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Setoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack R.","family":"Wands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Kuei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.canlet.2023.216493_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2023.216493_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.canlet.2023.216493_bib3","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"issue":"14","key":"10.1016\/j.canlet.2023.216493_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canlet.2023.216493_bib5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/COC.0b013e31818c08ff","article-title":"Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer","volume":"32","author":"Lee","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2023.216493_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharmaceut. Bull."},{"issue":"7782","key":"10.1016\/j.canlet.2023.216493_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.canlet.2023.216493_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"8","key":"10.1016\/j.canlet.2023.216493_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450116666150223121508","article-title":"Molecular bases of chemoresistance in cholangiocarcinoma","volume":"18","author":"Marin","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.canlet.2023.216493_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drup.2016.06.005","article-title":"The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: insights from knockout and humanized mice","volume":"27","author":"Durmus","year":"2016","journal-title":"Drug Resist. Updates"},{"issue":"2","key":"10.1016\/j.canlet.2023.216493_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2362.2007.01916.x","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas","volume":"38","author":"Rau","year":"2008","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.canlet.2023.216493_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00240","article-title":"Predictive and prognostic properties of human equilibrative nucleoside transporter 1 expression in gemcitabine-treated pancreatobiliary cancer: a meta-analysis","volume":"3","author":"Vos","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.canlet.2023.216493_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41416-018-0244-1","article-title":"Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study","volume":"119","author":"Blagden","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2023.216493_bib14","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1002\/onco.13598","article-title":"A phase ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)","volume":"26","author":"McNamara","year":"2021","journal-title":"Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216493_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13703","article-title":"In regard to \"A phase ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)\"","volume":"26","author":"Ricci","year":"2021","journal-title":"Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2023.216493_bib16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/1535-7163.MCT-11-1040","article-title":"DNA damage repair pathways in cancer stem cells","volume":"11","author":"Maugeri-Sacca","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"issue":"12","key":"10.1016\/j.canlet.2023.216493_bib17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat. Genet."},{"issue":"7274","key":"10.1016\/j.canlet.2023.216493_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2023.216493_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"7813","key":"10.1016\/j.canlet.2023.216493_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski","year":"2020","journal-title":"Nature"},{"issue":"6127","key":"10.1016\/j.canlet.2023.216493_bib21","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.canlet.2023.216493_bib22","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1158\/2159-8290.CD-20-0288","article-title":"Identification of BBOX1 as a therapeutic target in triple-negative breast cancer","volume":"10","author":"Liao","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216493_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcdb.2019.05.031","article-title":"The multifaceted contribution of alpha-ketoglutarate to tumor progression: an opportunity to exploit?","volume":"98","author":"Abla","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.canlet.2023.216493_bib24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41568-020-00303-3","article-title":"2-Oxoglutarate-dependent dioxygenases in cancer","volume":"20","author":"Losman","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2023.216493_bib25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1172\/JCI118918","article-title":"Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma","volume":"98","author":"Lavaissiere","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.canlet.2023.216493_bib26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.28411","article-title":"Aspartate beta-hydroxylase modulates cellular senescence through glycogen synthase kinase 3beta in hepatocellular carcinoma","volume":"63","author":"Iwagami","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.canlet.2023.216493_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/bjc.1995.107","article-title":"Establishment of a new human extrahepatic bile duct carcinoma cell line (OCUCh-LM1) and experimental liver metastatic model","volume":"71","author":"Yamada","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2023.216493_bib28","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/hep.26135","article-title":"Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis","volume":"57","author":"Huang","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.canlet.2023.216493_bib29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.22088","article-title":"A novel \"patient-like\" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines","volume":"47","author":"Sirica","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.canlet.2023.216493_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150336","article-title":"Anti-tumor effects of second generation beta-hydroxylase inhibitors on cholangiocarcinoma development and progression","volume":"11","author":"Huang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2023.216493_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.04.041","article-title":"Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation","volume":"429","author":"Huang","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2023.216493_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molcel.2020.09.018","article-title":"Phosphorylation of PDHA by AMPK drives TCA cycle to promote cancer metastasis","volume":"80","author":"Cai","year":"2020","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.canlet.2023.216493_bib33","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res."},{"issue":"375","key":"10.1016\/j.canlet.2023.216493_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.canlet.2023.216493_bib35","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.celrep.2015.11.029","article-title":"Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents","volume":"13","author":"Wang","year":"2015","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.canlet.2023.216493_bib36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.canlet.2023.216493_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ijo.2014.53","article-title":"Mapping of the circulating metabolome reveals alpha-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease","volume":"39","author":"Rodriguez-Gallego","year":"2015","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.canlet.2023.216493_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nprot.2006.5","article-title":"The comet assay: a method to measure DNA damage in individual cells","volume":"1","author":"Olive","year":"2006","journal-title":"Nat. Protoc."},{"issue":"5","key":"10.1016\/j.canlet.2023.216493_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response: convergence of drugs and pathways","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer Biol. Ther."},{"issue":"5721","key":"10.1016\/j.canlet.2023.216493_bib40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.1108297","article-title":"ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex","volume":"308","author":"Lee","year":"2005","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.canlet.2023.216493_bib41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cell.2005.12.041","article-title":"TopBP1 activates the ATR-ATRIP complex","volume":"124","author":"Kumagai","year":"2006","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.canlet.2023.216493_bib42","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.embor.embor925","article-title":"The MRN complex: coordinating and mediating the response to broken chromosomes","volume":"4","author":"van den Bosch","year":"2003","journal-title":"EMBO Rep."},{"issue":"7","key":"10.1016\/j.canlet.2023.216493_bib43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.canlet.2023.216493_bib44","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/hep.31486","article-title":"Ten-eleven translocation 1 promotes malignant progression of cholangiocarcinoma with wild-type isocitrate dehydrogenase 1","volume":"73","author":"Bai","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.canlet.2023.216493_bib45","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41588-022-01119-7","article-title":"YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis","volume":"54","author":"Wu","year":"2022","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.canlet.2023.216493_bib46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ccell.2016.05.018","article-title":"Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2","volume":"30","author":"Inoue","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216493_bib47","doi-asserted-by":"crossref","DOI":"10.1096\/fj.201800547R","article-title":"IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity","author":"Khurshed","year":"2018","journal-title":"Faseb. J."},{"issue":"6","key":"10.1016\/j.canlet.2023.216493_bib48","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523004445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523004445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:11:34Z","timestamp":1759594294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523004445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":48,"alternative-id":["S0304383523004445"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216493","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216493"}}